Ibupiretas

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ibupiretas

What is Ibupiretas?

Ibupiretas is a pharmaceutical formulation that contains ibuprofen as its active ingredient. It belongs to a class of medications known as nonsteroidal anti-inflammatory drugs (NSAIDs). These medications are primarily used for their ability to reduce inflammation, alleviate pain, and lower body temperature during fever.

Mechanism of Action

The active component in Ibupiretas works by inhibiting the activity of enzymes called cyclooxygenases (COX-1 and COX-2). These enzymes play a central role in the production of prostaglandins, which are lipid compounds produced at sites of tissue damage or infection. By reducing the synthesis of prostaglandins, the medication helps to diminish the sensations of pain and the physiological processes that lead to swelling and fever.

Therapeutic Properties

Ibupiretas is characterized by three main therapeutic properties:

  • Analgesic: It helps in the management of mild to moderate pain.
  • Anti-inflammatory: It assists in reducing redness and swelling associated with various conditions.
  • Antipyretic: It is effective in reducing elevated body temperatures.

General Characteristics

As an NSAID, the medication is designed to provide symptomatic relief. It is frequently available in various forms, such as tablets or chewable formats, to accommodate different patient needs. While it addresses the symptoms of pain and inflammation, it does not treat the underlying cause of the condition itself but rather manages the body's response to it.

Regulatory References

  1. National Institutes of Health (NIH) MedlinePlus

What side effects are possible with Ibupiretas?

Possible Side Effects and Safety Information

The safety profile for Ibupiretas, which contains Ibuprofen, is formally established by regulatory bodies, classifying potential adverse reactions by the physiological system affected and their expected frequency.

Key Adverse Reaction Classifications

Classification Examples of Reactions Description
Common (Gastrointestinal) Nausea, vomiting, dyspepsia, abdominal pain, diarrhea These are frequently documented side effects, often related to the digestive system.
Uncommon (Immune/GI) Hypersensitivity reactions (e.g., pruritus, hives), gastrointestinal ulceration, bleeding Reactions occurring less frequently but requiring specific monitoring in regulatory documents.

Serious Safety Considerations

The official labeling highlights risks that are rare but clinically significant. Serious risks include potentially fatal gastrointestinal bleeding, ulceration, or perforation, which can occur without warning symptoms. Additionally, the use of high-dose and long-term Ibuprofen may be associated with a small increased risk of arterial thrombotic events, such as myocardial infarction or stroke. Regulatory documents also specify the risk of Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome.

Population and Exposure Constraints

The safety profile notes specific considerations for certain groups: Older adults are documented to have an increased frequency of adverse reactions, particularly fatal gastrointestinal events. Risk is also linked to duration; the risk of thrombotic events is associated with long-term and high-dose exposure. Furthermore, the medicine can officially mask symptoms of underlying infections, potentially delaying appropriate medical assessment.

Overdose and Emergency Response

Ibupiretas overdose is associated with documented manifestations of systemic toxicity ranging from common gastrointestinal effects to severe neurological signs. Initial presentations often include nausea, vomiting, stomach pain, drowsiness, confusion, and lethargy. More serious outcomes are officially noted, including the risk of Acute Renal Failure, Metabolic Acidosis, seizures (convulsions), and cardiovascular signs like shock (severe hypotension). The central nervous system may also exhibit signs such as blurred vision and Tinnitus.

Immediate Action Mandates

Official regulatory documents require individuals to seek immediate medical attention or contact a Poison Control Center right away in all cases of suspected overdose, regardless of the patient’s apparent condition. Since no specific antidote is known for acute toxicity, the required management is limited entirely to symptomatic and supportive treatment, potentially involving procedures like the administration of activated charcoal.

Monitoring and Risk Factors

Hospital monitoring is necessary for observation and specialized care, often including the continuous assessment of vital signs and tests (such as ECG and blood/urine analyses) to detect internal injury. The official guidance notes increased risk of unwanted effects in elderly patients and cites specific ingestion thresholds for observation in children.

Therapeutic Uses of Ibupiretas

What Ibupiretas Treats: Main Uses and Benefits

Ibupiretas generally plays a role in managing distressing symptoms, offering supportive therapeutic benefit across domains where symptoms may become intense or disruptive. It is considered relevant in conditions involving acute or episodic manifestations and is used in settings where short-term symptomatic assistance is needed. The medication is commonly applied across various conditions characterized by these acute or episodic occurrences.

It is relevant for easing symptom clusters related to inflammatory or irritative states, typically addressing pain, fever, and localized inflammation. These core indications include relief from headache, toothache, minor arthritis pain, muscle aches, sprains, and the discomfort of menstrual cramps.

The application of this medication generally contributes to easing the overall symptom load, supporting general well-being during symptomatic phases. This benefit assists with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Role in Managing Episodic Discomfort

Symptom Domain Common Scenarios of Use Patient Benefit
Pain & Swelling Soft tissue injuries (sprains, strains), minor arthritis pain. Supports joint comfort and may assist in easing physical discomfort.
Fever Common cold, flu-like symptoms, post-vaccination fever. Helps ease the overall systemic symptom load.
Episodic Aches Headaches, toothaches, menstrual cramps. Provides supportive relief during episodes of heightened discomfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ibupiretas? (Official Regulatory Eligibility)

Eligibility for Ibupiretas (Ibuprofen) is determined by age, pre-existing conditions, and physiological status, as defined by regulatory authorities. The medicine is contraindicated (must not be used) in several specific populations.

Absolute Contraindications

Ibupiretas must not be used by patients with a history of asthma or allergic reactions to other NSAIDs (Nonsteroidal Anti-inflammatory Drugs) or aspirin. Use is also prohibited for individuals with active or recurrent peptic ulcer/haemorrhage, or a history of gastrointestinal bleeding related to previous NSAID use. It is contraindicated in patients with severe heart failure (NYHA Class IV), severe renal impairment, or severe hepatic impairment.

Age and Pregnancy Restrictions

Population Regulatory Status
Infants under 6 months Not recommended or Contraindicated
Older Adults Use with caution (Increased risk of adverse reactions)
Third Trimester of Pregnancy Contraindicated
First/Second Trimester Restricted (Use only if clearly necessary)

For other patient populations, such as those with mild to moderate organ impairment, hypertension, or certain inflammatory bowel conditions (e.g., Crohn's Disease), the medicine is only to be used with caution.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Ibupiretas (Ibuprofen) is structured around official regulatory data concerning contraindicated combinations and clinically significant risks of altered drug exposure or pharmacodynamic reinforcement.


Formal Restrictions and Contraindications

Classification Interacting Agents
Contraindicated Combinations Other NSAIDs (including COX-2 inhibitors), Aspirin (doses greater than 75 mg/day), and other Ibuprofen-containing products.
Pharmacodynamic Risk Anticoagulants (e.g., Warfarin), Corticosteroids, and SSRIs. Co-administration increases the risk of bleeding or gastrointestinal ulceration.

Exposure Modification and Timing Rules

Ibuprofen can affect the body's handling of certain co-administered medicines, or its own elimination. Medicines such as Lithium, Digoxin, and Methotrexate may have their plasma concentrations increased due to reduced renal clearance caused by Ibuprofen. The use of strong CYP2C9 inhibitors (e.g., Fluconazole) may increase the exposure of Ibuprofen in the body.

For patients taking low-dose Aspirin for antiplatelet purposes, regulatory documents mandate a timing separation to avoid interference. Immediate-release Ibuprofen should be taken at least 8 hours before or at least 30 minutes after the Aspirin dose.

Interaction risk is officially noted as being increased in elderly patients, particularly regarding the risk of gastrointestinal bleeding. Furthermore, the combination of Ibuprofen and alcohol is documented to increase the risk of gastrointestinal irritation.

Mechanism of Action

The action of Ibupiretas is defined by its molecular interaction with the Cyclooxygenase (COX) enzyme pathway, which modulates key endogenous mediators involved in thermoregulation and nociceptive signaling. The molecule functions as a reversible, competitive inhibitor of both the COX-1 and COX-2 isoforms. This interaction inhibits the initial step in the conversion of the substrate Arachidonic Acid into prostaglandins (PGs) and thromboxanes. Limiting the generation of these lipid mediators curtails the prostaglandin-mediated component of biological signaling.

This reduction in prostaglandins initiates simultaneous physiological changes: Centrally, it lowers the concentration of PGE2 in the hypothalamus, facilitating the resetting of the elevated thermoregulatory set-point. Peripherally, the lowered local PG levels reduce the sensitization of nociceptors (pain-sensing neurons). This dual action modulates nociceptive signaling and mitigates PG-driven local vasodilation and increased vascular permeability.

Dosage and Administration Information

Official Administration Guidelines

Ibupiretas, which contains Ibuprofen, is administered through several official routes depending on the specific formulation. The most common routes are oral (using tablets, capsules, or suspension) and, for certain products, rectal (suppositories) or intravenous (IV) infusion in a clinical setting.


Administration Scope Official Instructions
Dosing Schedule (Adult) Standard oral dosing for general relief is typically 200 mg to 400 mg per dose. The maximum daily dose for over-the-counter (OTC) use is 1200 mg. For prescription use in inflammatory conditions, the maximum daily dose may be up to 3200 mg in divided doses.
Frequency and Timing Doses are separated by a minimum interval of four to six hours. The medication may be taken with food or milk to mitigate potential gastrointestinal discomfort, though absorption is not significantly altered by food.
Age-Group Rules Dosing for pediatric patients (children 6 months and older) is calculated strictly based on body weight (mg/kg) using the appropriate liquid concentration and a calibrated measuring device.
Preparation & Use Oral suspensions must be shaken well before measurement to ensure uniform dosage. Intravenous solutions require dilution and must be administered as an infusion over a specified time (e.g., 30 to 60 minutes).

Official instructions strictly mandate using the lowest effective dose for the shortest duration necessary. If a dose is missed, it is generally recommended to take it when remembered, provided the next scheduled dose adheres to the mandatory time interval, ensuring the maximum daily limit is not exceeded.

Recent Clinical Evidence

Evidence for Acute Symptomatic Relief (Pain and Fever)

Research into Ibupiretas was studied for conditions associated with acute episodes, specifically to explore outcomes related to physical discomfort (such as headache or toothache) and systemic imbalance (fever). Most evidence consists of Randomized Controlled Trials (RCTs) and Meta-analyses, comparing the medicine to placebo or other options. Studies research examined how endpoints related to pain intensity or temperature readings were monitored over short intervals.

Findings describe patterns observed within the first 24 to 48 hours. The majority of this evidence focuses on short-term outcomes, and follow-up durations were limited. Researchers have also noted that evidence quality varies across studies due to differences in protocols.


Evidence for Inflammation-Related Discomfort and Recurrent Symptoms

The medicine was evaluated in research settings addressing fluctuating conditions, such as discomfort associated with minor arthritis and menstrual cramps. Research explored short-term RCTs and large-scale observational studies. Outcomes measured included patient-reported discomfort and functional activity levels.

Long-term effects are not fully established by prospective, controlled trials. Evidence regarding prolonged, regular usage and its association with various health outcomes is mainly derived from observational studies, meaning certainty remains low regarding sustained effects.


Long-Term Research and Study Follow-Up

Most core interventional research focuses on short-term symptom changes. Long-term research comes primarily from large-scale epidemiological studies that track usage trends. This evidence contributes to understanding patterns over time but research does not determine whether an individual will respond similarly over an extended duration.


Evidence in Special Populations

Ibupiretas was studied for use in specific demographic groups, including pediatric patients (children). In addition, large observational studies monitored research scenarios involving older adults. Evidence for certain subgroups, such as patients with multiple comorbidities, is limited and heterogeneous. The existing research highlights that results apply only to the populations studied.


What Remains Uncertain in the Research Landscape

Evidence highlights what is known—and what is still uncertain. The major gaps often center on limited follow-up durations in many interventional trials. Data for certain groups remain insufficient. Long-term effects are not fully established by controlled trials, and comparative evidence against every available treatment may be lacking in some areas.

Key Studies & References

  1. Combined and alternating paracetamol and ibuprofen therapy for febrile children (Cochrane Review)
  2. Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever (NCBI/HSR Review)

Frequently Asked Questions (FAQ)

Common questions about Ibupiretas (FAQ)


Q: Can Ibupiretas affect the effectiveness of blood pressure medications?

Regulatory documents indicate that Ibuprofen, the active ingredient in Ibupiretas, may potentially reduce the blood pressure-lowering effects of certain medications used to treat high blood pressure (antihypertensives). Patients are generally informed to discuss their medication regimen with a healthcare provider to understand any potential impact.


Q: Is it normal to experience dizziness or drowsiness after taking Ibupiretas?

Official product information lists both dizziness and drowsiness as potential adverse reactions that some people may experience while taking this medication. This is a recognized side effect that is documented in regulatory labeling.


Q: Are there specific signs of a serious stomach issue (like bleeding) that should be watched for while taking Ibupiretas?

While the risk of serious gastrointestinal issues like bleeding can occur without warning, official warnings advise monitoring for specific signs. These signs include passing black or tarry stools or experiencing vomiting that resembles coffee grounds. If observed, these signs are documented in official safety information as reasons to seek medical assessment.


Q: Are there any known interactions between Ibupiretas and herbal supplements?

Official regulatory documents contain general information that all supplements, including herbal products, should be brought to the attention of a healthcare professional. This is particularly relevant for supplements that may have an effect on blood clotting or have blood-thinning properties.


Q: Can Ibupiretas cause fluid retention or swelling in the hands or feet?

Studies and regulatory labeling note that fluid retention and edema (swelling) have been observed in some individuals taking medications in the NSAID class. This effect is documented in the official safety information.


Q: What is the general guidance on using Ibupiretas while breastfeeding?

According to official regulatory and medical sources, Ibuprofen is considered compatible with breastfeeding due to the small amounts of the medicine that are excreted into breast milk. The use of this medication should align with official guidance regarding dosage and duration.


Q: Does Ibupiretas interact with medications used for managing diabetes?

Official regulatory data includes reports of an association between Ibuprofen and low blood sugar (hypoglycemia). This is mainly noted in individuals who already have pre-existing diabetes. Official information indicates that individuals taking diabetes medication should seek specific guidance.


Q: Why do some people experience ringing in the ears (tinnitus) as a side effect?

Ringing in the ears, medically termed tinnitus, is documented and listed in the official regulatory adverse reactions section for this medication. This means it is a known and recognized potential side effect.


Q: Is there a maximum number of days Ibupiretas should be used without consulting a professional?

For over-the-counter (OTC) use, official regulatory guidelines typically limit use to a maximum duration of 10 days for pain relief or 3 days for fever reduction. The guidance specifies limits for non-prescription use, and use beyond those limits is typically managed with professional oversight.


Q: Does Ibupiretas interact with birth control pills?

Official product information suggests that Ibuprofen may interact with certain specific types of oral contraceptives, particularly those containing drospirenone. This interaction may potentially increase the risk of high potassium levels. General patient guidance emphasizes the importance of reviewing all medications with a healthcare professional.


Q: Is there any information on the effect of Ibupiretas on fertility in women?

Regulatory documents indicate that the use of this class of medication is generally not recommended for women who are actively trying to conceive. This is because official data suggests it may temporarily affect or impair female fertility.

How should Ibupiretas be stored and disposed of?

The storage and disposal of Ibupiretas, which contains Ibuprofen, must strictly adhere to the conditions mandated in the official regulatory labeling.


Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, between 20°C and 25°C (68°F and 77°F).
Protection Protect from excessive moisture and heat; do not freeze the product.
Container Keep the medicine in the original container and ensure it is tightly closed.
Child Safety The medicine must be kept out of the sight and reach of children.

Disposal Requirements

Official disposal procedures forbid discarding unused or expired product via household trash or wastewater (e.g., toilet or sink). Disposal must follow local regulatory requirements for unused medicine, or utilize authorized drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ibupiretas found in:

A-Z Index: